1naresh
Array
(
[urn:ac.highwire.org:guest:identity] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:identity
[type] => guest
[service-id] => ajnr-ac.highwire.org
[access-type] => Controlled
[privilege] => Array
(
[urn:ac.highwire.org:guest:privilege] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:privilege
[type] => privilege-set
[privilege-set] => GUEST
)
)
[credentials] => Array
(
[method] => guest
)
)
)
1nareshArray
(
[urn:ac.highwire.org:guest:identity] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:identity
[type] => guest
[service-id] => ajnr-ac.highwire.org
[access-type] => Controlled
[privilege] => Array
(
[urn:ac.highwire.org:guest:privilege] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:privilege
[type] => privilege-set
[privilege-set] => GUEST
)
)
[credentials] => Array
(
[method] => guest
)
)
)
Table 1: Patient demographics
Demographics No. of subjects 44 Median age at inclusion (yr) 31 (range, 21–62) Sex (M/F) 8:36 Diagnosis at inclusion (possible MS/MS) 23/21 Diagnosis at 1-year follow-up (possible MS/MS) 16/28 Relapsea at inclusion (yes/no) 22/22 Relapse at 1-year follow-up (yes/no) 4/40 Median EDSS at inclusion 2 (range, 0–5) Median EDSS at 1-year follow-up 1.25 (range, 0–4)
Note:—EDSS indicates Expanded Disability Status Scale.
↵a A “relapse” was defined as new symptoms or worsening of previous symptoms, lasting >24 hours and in the absence of increased body temperature and infection.